ArticlePloS one2025
Notch2/3-DLL4 interaction in urothelial cancer cell lines supports a tumorigenic role of Notch signaling pathways in bladder carcinoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma.Oncogene · 2026Article
- Single-cell and spatial transcriptomics reveal a DLL4-associated tip-like endothelial niche linked to neoadjuvant chemotherapy non-response in muscle-invasive bladder cancer.Translational oncology · 2026Article
- Bladder Cancer: Uncovering the Predictive Role of NOTCH as an Emerging Candidate Biomarker for Therapeutic Strategies.Cancers · 2025Review
- Recent advances in bladder cancer stem cells (BCSCs): A descriptive review of emerging therapeutic targets.iScience · 2025Review
- Integrated single-cell genomics, transcriptomics, and pathomics to identify potential biomarkers in muscle-invasive bladder cancer.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Notch pathway plays an important role in many aspects of cancer biology and acts in a dichotomous way in bladder cancer. The mechanisms behind this behavior are still elusive. Here, we analyzed DLL4 and Notch receptor expression, interaction and downstream signaling in human bladder cancer cells. MATERIALS AND
methodsThe expression levels of Notch pathway components (Notch1-4, DLL4, HES1, HEY1) were assessed in papillary (G1: RT-4) and non-papillary bladder cancer cell lines (G2-G4: RT-112, 647-V, T-24, KU-19-19, CAL-29) by qRT-PCR and immunofluorescence. Expression data were validated by analyzing data from open-source databases (CCLE; TCGA). The endogeneous interactions of Notch2/Notch3 receptors and the ligand DLL4 were studied by in situ proximity ligation assay. Activation of canonical Notch signaling was evaluated by stimulation with recombinant DLL4 protein.
resultsAll Notch targets were expressed, with Notch2 and Notch3 showing the highest expression levels. Endogeneous interactions between Notch2/3 and DLL4 were detected in all BCa cell lines. Amounts of Notch2/3-DLL4 complexes were high in RT-112 and CAL-29, while RT-4/647-V showed moderate and T-24, KU-19-19 low abundance. Proportion of (peri-) nuclear interaction complexes correlated negatively with Notch downstream targets. DLL4 stimulation resulted in canonical Notch pathway activation and increased tumor cell viability and proliferation in RT-4, 647-V, T-24 and KU-19-19 cells. DISCUSSION: The Notch signaling pathway can discriminate between different receptors and may play an essential role in the progression of bladder carcinoma. We demonstrated for the first time direct interactions between DLL4 and Notch2/3 associated to activation of canonical downstream Notch signaling and increased tumor cell behavior in human bladder cancer cells. Our data support the view that the Notch2/3-DLL4 axis plays an oncogenic role in bladder cancer. Further analyses of Notch signaling in bladder cancer can promote the development of tailored anti-DLL4/Notch bladder cancer therapies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.